Dr Reddy’s Q4FY26 Preview: Profit Seen Down 34%

Sector setup: March quarter growth, but margins under pressure

Indian pharmaceutical companies are expected to post aggregate sales growth of about 9% year-on-year in the March 2026 quarter (Q4FY26). However, brokerages expect Ebitda growth to stay muted at roughly 1%, largely due to an elevated base in the US business. Benign raw material prices and a recovery in domestic acute demand are cited as supportive factors. At the same time, higher freight costs linked to the US-Iran conflict are seen offsetting part of that benefit. Within this broader backdrop, Dr Reddy’s Laboratories is heading into Q4FY26 with a weaker earnings picture versus last year.

Consensus snapshot: revenue, profit and Ebitda estimates

Brokerage estimates tracked by Business Standard suggest Dr Reddy’s net profit for Q4FY26 could come in at ₹1,035 crore. That implies a 34% year-on-year decline compared with ₹1,587 crore in Q4FY25. On a sequential basis, the company’s bottom line is projected to decline 13%.

Revenue is expected to decline 3.35% year-on-year to ₹8,220 crore versus ₹8,506 crore in Q4FY25. Compared with the December 2025 quarter (Q3FY26) revenue of ₹8,726.8 crore, the estimate implies a 5.8% sequential drop.

Ebitda is expected to decline by over 20% year-on-year to ₹1,629 crore from ₹2,051 crore in Q4FY25. It is also seen falling around 14% quarter-on-quarter from ₹1,895 crore in Q3FY26. The estimates collectively reflect a quarter where the US contribution is expected to soften, while India remains the key growth lever.

The main drag: North America weakness as Revlimid fades

Kotak Institutional Equities expects Dr Reddy’s to report a 10% year-on-year decline in overall sales. The brokerage attributes this primarily to a sharp 33% quarter-on-quarter drop in North America revenues to $126 million. Kotak links the decline to the tapering off of generic Revlimid, factoring in nil contribution due to patent expiry and one-time shelf stock adjustments.

YES Securities and PL Capital also take a cautious view on the US trajectory, noting that the US business will likely decline or remain in low single digits as the Revlimid tailwind fades. The underlying message across these views is that the high-margin phase of the Revlimid opportunity is no longer expected to support quarterly earnings in the way it did previously.

A more balanced view: Centrum’s expectations for the US business

Centrum Broking’s estimates indicate a different near-term shape for the US segment. It expects an 8% year-on-year growth in the US business, with sales reaching $110 million in constant currency terms. This sits alongside the broader market expectation that base US generics continues to face pricing pressure.

In practice, the spread between $126 million (North America, per Kotak’s Q-o-Q view) and $110 million (US sales, per Centrum’s Y-o-Y view) highlights how assumptions around product mix, Revlimid contribution, and near-term stocking dynamics can materially change quarterly expectations.

India business: projected to stay in double-digit growth

While the US outlook is mixed, brokerages generally position India as a significant growth driver for Dr Reddy’s. Centrum Broking and Kotak project double-digit expansion for the India business in the range of 15% to 18% year-on-year. The expected growth is linked to performance in key therapies and the integration of the Nestle and Sanofi portfolios.

Centrum also projects domestic formulations to rise 15% year-on-year to ₹1,400 crore. This domestic momentum is important in a quarter where US-linked profitability is expected to be under pressure and where investors may be looking for stability in core franchises.

Europe and Russia: steady traction cited by brokerages

Outside the US and India, Kotak flags steady gains in Europe and volume-led growth of 26% in Russia. The article also notes Europe traction led by the nicotine replacement therapy (NRT) portfolio, supporting the narrative that diversification across regions can help cushion some of the volatility from the US generics cycle.

That said, the March quarter focus remains primarily on whether India and other international markets can offset the US decline enough to limit the damage to consolidated margins.

Profitability: margin compression is central to the Q4FY26 debate

Kotak expects consolidated Ebitda to decline 30% year-on-year, with margins contracting to 19%. The brokerage links margin pressure to lower gross margins and the loss of high-margin generic contributions. At a sector level too, brokerages cite muted Ebitda growth for Indian pharma in Q4FY26, despite stronger topline trends.

Cost headwinds are also part of the setup. While raw material prices are described as benign, higher freight costs linked to the US-Iran conflict are expected to offset some benefits. With Revlimid-related profitability fading, the operating leverage from the US business is likely to be a key swing factor in quarterly margins.

Other overhangs: Brazil rejection, GLP-1 uncertainty, and regulatory watch

Market experts cited in the provided text point to Dr Reddy’s diabetes and weight loss drug rejection in Brazil as another factor weighing on near-term expectations. Separately, Morgan Stanley cut earnings estimates for Dr Reddy’s to 10.7% for FY2025-26 and expects revenues from North America to drop 21% in the same period. The note also flags the Revlimid phase-out and GLP-1 uncertainty as factors that could weigh on earnings.

Additional watchpoints mentioned include sponsor concentration in the US, where three products account for about 40% of US revenue, and a USFDA inspection overhang at Duvvada. Currency headwinds are also listed as a risk factor.

Key dates and what investors will watch

The text includes multiple references to the Q4FY26 result timing. One section says the company is set to announce its fourth quarter results on Tuesday, May 12, 2026. Another section states Dr Reddy’s is scheduled to announce Q4 FY26 results on April 29, 2026, described as a board meeting date for approval.

Beyond the headline numbers, the article flags key metrics to monitor: revenue performance versus estimates of ₹8,200 crore to ₹8,600 crore, PAT versus ₹950 crore to ₹1,050 crore, management guidance for FY27, US revenue and pipeline updates, dividend declaration, and commentary on macro headwinds.

Market cues: ADR trading snapshot on NYSE

In the US market snapshot provided, Dr Reddy’s ADR (NYSE: RDY) closed at $13.14, down $1.09 (0.64%). In extended trading, it was quoted at $13.64, up $1.49 (3.76%). The same snapshot lists consensus EPS of $1.09 and expected revenue of $186.58 million, with actual figures marked as N/A in the feed.

Key numbers at a glance

Why this quarter matters

For Dr Reddy’s, Q4FY26 is shaping up as an inflection quarter where the market is recalibrating expectations after the fading of a high-margin US generic contribution. The dispersion in brokerage assumptions on the US business indicates that product-level dynamics, including the Revlimid phase-out and any one-time channel adjustments, remain central to quarterly outcomes.

At the same time, the India business is expected to do the heavy lifting, supported by therapy growth and portfolio integration, while Europe, Russia and other markets provide incremental support. Investors are also likely to focus on margin durability in an environment where freight costs have risen and US pricing pressure remains a structural theme.

Conclusion

Brokerage estimates suggest Dr Reddy’s could report a year-on-year decline in Q4FY26 profit and Ebitda, driven mainly by softer US sales as the generic Revlimid contribution tapers. The upcoming results, cited as May 12, 2026 in one report and April 29, 2026 in another, will be watched for US revenue trends, India growth, and management commentary on margins and pipeline priorities.